Results 21 to 30 of about 8,451 (198)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab

Respiratory Medicine Case Reports, 2019
We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-
Osamu Matsuno, Seijiro Minamoto
doaj   +1 more source

Response to mepolizumab treatment is sustained across 4-weekly dosing periods

ERJ Open Research, 2020
Background Mepolizumab (100 mg delivered s.c. every 4 weeks) is indicated for add-on maintenance treatment for patients with severe eosinophilic asthma. Mepolizumab has been shown to reduce exacerbations and the requirement for daily oral corticosteroids,
Ian D. Pavord, Eugene R. Bleecker, Roland Buhl, Pascal Chanez, Elisabeth H. Bel, Peter Howarth, Daniel J. Bratton, Frank C. Albers, Steven Yancey   +8 more
doaj   +1 more source

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

Allergy, Asthma & Clinical Immunology, 2021
Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian, Jane Jiyoon Park, Michael W. Tsoulis, Harold Kim   +3 more
doaj   +1 more source

Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.

, 2022
Mepolizumab, an anti-interleukin-5 (IL-5) antibody, reduces disease flares in patients with hypereosinophilic syndrome (HES).
Rothenberg, Marc E, HES Mepolizumab Study Group, Faguer, Stanislas, Kwon, Namhee, Gleich, Gerald J, Steinfeld, Jonathan, Roufosse, Florence, Mavropoulou, Eleni, Yancey, Steven W   +8 more
core   +1 more source

Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients [PDF]

, 2020
Background: Patients with severe asthma not meeting the strict trial eligibility criteria for mepolizumab are now routinely treated with this biological in clinical practice, but it remains unclear whether these ineligible patients respond differently to
Richards, Levi B., Neerincx, Anne H., Sont, Jaap K., Brinke, Anneke Ten, Weersink, Els J. M., Bel, Elisabeth H. D., van Bragt, Job J. M. H., Braunstahl, Gert-Jan, Aarab, Reim, Longo, Cristina, Maitland-van der Zee, Anke-Hilse   +10 more
core   +2 more sources

Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein–protein interaction analyses

Respiratory Research, 2023
Introduction Biomarkers are needed to inform the choice of biologic therapy in patients with asthma given the increasing number of biologics. We aimed to identify proteins associated with response to omalizumab and mepolizumab.
Ayobami Akenroye, Tanawin Nopsopon, Laura Cho, Matthew Moll, Scott T. Weiss   +4 more
doaj   +1 more source

Characteristics of new adult users of mepolizumab with asthma in the USA

BMJ Open Respiratory Research, 2021
Background In the USA, over 25 million people have asthma; 5%–10% of cases are severe. Mepolizumab (Nucala) is an interleukin-5 antagonist monoclonal antibody; it was approved by the FDA in 2015 as add-on maintenance treatment of severe asthma for ...
Pamela M McMahon, Ann Chen Wu, Emily Welch, Cheryl N McMahill-Walraven, Aziza Jamal-Allial, Mia Gallagher, Tancy Zhang, Christine Draper, Anne Marie Kline, Leslie Koerner, Jeffrey S Brown, Melissa K Van Dyke   +11 more
doaj   +1 more source

A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils

Heliyon, 2022
Background and aims: Biologics that target Type 2 inflammation are effective in reducing exacerbations of severe asthma. We conducted a systematic review and integrated analysis of the efficacy and safety of these biologics in chronic obstructive ...
Hiroshi Ohnishi, Masamitsu Eitoku, Akihito Yokoyama   +2 more
doaj   +1 more source

Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE)

Clinical and Translational Allergy, 2022
Background Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation. The effects of these compound on the immunoglobulin (Ig)E T2 component are virtually
Marco Contoli, Pierachille Santus, Francesco Menzella, Cindy Rocchi, Dejan Radovanovic, Federico Baraldi, Chiara Martelli, Serena Casanova, Carlo Barbetta, Claudio Micheletto, Nicola Scichilone, Bianca Beghè, Elisiana Carpagnano, Alberto Papi   +13 more
doaj   +1 more source

Treatment of patients with the hypereosinophilic syndrome with mepolizumab. [PDF]

, 2008
BACKGROUND: The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause.
Parkin, Jacqueline M., Frewer, Paul I. H., Kahn, J.E., Rothenberg, Marc E., Parkin, Jacqueline M, Weller, Peter F., Roufosse, Florence E, Weller, Peter F, Klion, Amy D, Haig, Ann E, Schwartz, Lawrence B., Haig, Ann E., Rosenwasser, Lanny J, Rothenberg, Marc E, Schwartz, Lawrence B, Griffin, Elaine F, Frewer, Paul I H, Klion, Amy D., Roufosse, Florence, Ring, Johannes, Simon, Hans-Uwe, Rosenwasser, Lanny J., Kahn, Jean E., Griffin, Elaine F., Gleich, Gerald J, Roufosse, Florence E., Gleich, Gerald J., Kahn, Jean Emmanuel   +27 more
core   +1 more source